The table below shows Foghorn Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$25.27M
-$23.97M
-$29.34M
-$31.18M
$271.53M
-$23.15M
Capital expenditure
$0.00
$28.00K
$101.00K
$636.00K
$247.00K
$1.79M
Investing cash flow
-$17.72M
$29.40M
$27.09M
$29.50M
-$159.41M
-$3.26M
Dividends paid
-
-
-
-
FHTX operating cash flow (10-K history)
Foghorn Therapeutics Inc. reported operating cash flow of -$86.10M for fiscal year 2025. That is up 14.2% from -$100.41M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$46.34M (FY 2019) to -$86.10M. Figures come from the company's audited annual reports as filed with the SEC.